F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism · 15.07.2025 · 110 (8) · 2299-2306
DOI: 10.1210/clinem/dgae788 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.11.2024. Verfasst von Bowen Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Rensselaer-Icahn School of Medicine at Mount Sinai Center for Engineering and Precision Medicine, New York, NY 10019, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, F2-Isoprostanes, Fractures, Bone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Dr. and Ms. Sands and Sands Family for Orthopaedic Research, National Institute of Health.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Fracture risk is higher in type 2 diabetes (T2D) for a given bone mineral density (BMD) level. Increased oxidative stress in T2D induces diabetic complications and may affect T2D bone fragility.
Objective
To investigate whether the levels of plasma F2-isoprostanes, a reliable oxidative stress marker, are associated with incident clinical fracture risk in older adults with diabetes.
Methods
An observational cohort study was conducted in a well-characterized cohort from Health, Aging, and Body Composition study.
Participants
Older Black and White ambulatory adults with baseline plasma F2-isoprostanes measurements (baseline age 70-79 years, T2D: N = 132; nondiabetes: N = 571) were selected from the study cohort of 3075 individuals. Risk of incident clinical fractures was assessed.
Results
In the Cox proportional hazard model with multivariate adjustments (including BMD, medications, and other risk factors), a 93% increase in incident clinical fracture risk was significantly associated with each SD increase in log plasma F2-isoprostanes in the T2D group (hazard ratio [HR] = 1.93 [95% CI, 1.26-2.9] P = .002), but there was no evidence of an association in the nondiabetes group (HR = 0.98 [95% CI 0.81-1.18] P = .79, P for interaction <.001). Log plasma F2-isoprostanes were moderately correlated with a decline in baseline total hip BMD (r = −0.25, P = .003), and with a 4-year decrease in total hip BMD (r = −0.28, P = .008) in T2D. There was no evidence of correlation between log plasma F2-isoprostanes and circulating glycoxidation markers or bone turnover markers in either group.
Conclusion
Plasma F2-isoprostanes levels in individuals with diabetes are associated with increased incident clinical fracture risk independently of baseline BMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rensselaer-Icahn School of Medicine at Mount Sinai Center for Engineering and Precision Medicine, New York, NY 10019, USA.
- Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
- Center for Mineral Metabolism and Clinical Research, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Division of Endocrinology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94143, USA.
ORCID-Profile: Ann V Schwartz, Deepak Vashishth
Förderung
- NIA NIH HHS
- Dr. and Ms. Sands and Sands Family for Orthopaedic Research
- National Institute of Health
- Intramural Research Program
- NIH
- NINR NIH HHS
- National Institute on Aging
- NIA
Zitieren
APA
Wang, B., Dhaliwal, R., Ewing, S. K., Schwartz, A. V., & Vashishth, D. (2025). F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 110(8), 2299-2306. https://doi.org/10.1210/clinem/dgae788
Vancouver
Wang B, Dhaliwal R, Ewing SK, Schwartz AV, Vashishth D. F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025;110(8):2299-2306. doi:10.1210/clinem/dgae788
BibTeX
@article{Wang2025,
author = {Wang, Bowen and Dhaliwal, Ruban and Ewing, Susan K and Schwartz, Ann V and Vashishth, Deepak},
title = {F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {8},
pages = {2299--2306},
doi = {10.1210/clinem/dgae788}
}
EUVIMED